{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:57:44Z","timestamp":1792735064379,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.msard.2026.107024","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:29:26Z","timestamp":1768807766000},"page":"107024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Treatment outcomes of high-efficacy disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: A longitudinal observational study"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5436-5804","authenticated-orcid":false,"given":"Raed","family":"Alroughani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar Farouk","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107024_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104935","article-title":"Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina","volume":"79","author":"Alonso","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107024_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105330","article-title":"Ocrelizumab and Cladribine Had Similar EDSS Stability in Patients with Highly Active Multiple Sclerosis [online]","volume":"80","author":"Alroughani","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107024_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2024.108249","article-title":"Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study [online]","volume":"240","author":"Alroughani","year":"2024","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"17_supplement_2","key":"10.1016\/j.msard.2026.107024_bib0004","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000203140","article-title":"Ocrelizumab and Cladribine had similar EDSS stability and safety profile in patients with highly active multiple sclerosis (P8-3.011)","volume":"100","author":"Alshawaf","year":"2023","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.msard.2026.107024_bib0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/1352458517697830","article-title":"Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor [online]","volume":"24","author":"Arrambide","year":"2018","journal-title":"Mult. scler. (Houndmills Basingstoke Engl.)"},{"issue":"1","key":"10.1016\/j.msard.2026.107024_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40893-016-0002-2","article-title":"A real world experience with fingolimod in active RRMS patients na\u00efve to second-line agents: a 2 years, intention-to-treat, observational, single center study [online]","volume":"1","author":"Baroncini","year":"2016","journal-title":"Mult. Scler. Demyelinating Disord."},{"key":"10.1016\/j.msard.2026.107024_bib0007","article-title":"Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: a prospective cohort study from the German multiple sclerosis and pregnancy registry [online]","volume":"48","author":"Bast","year":"2025","journal-title":"Lancet Reg. Health - Eur."},{"key":"10.1016\/j.msard.2026.107024_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104166","article-title":"Self-assessment of people with relapsing-remitting and progressive multiple sclerosis towards burden of disease, progression, and treatment utilization\u2014Results of a large-scale cross-sectional online survey (MS Perspectives) [online]","volume":"68","author":"Bayas","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107024_bib0009","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of Initial Disease-modifying therapy with later conversion to secondary progressive multiple sclerosis [online]","volume":"321","author":"Brown","year":"2019","journal-title":"JAMa"},{"issue":"2","key":"10.1016\/j.msard.2026.107024_bib0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis [online]","volume":"321","author":"Brown","year":"2019","journal-title":"JAMa"},{"issue":"6","key":"10.1016\/j.msard.2026.107024_bib0011","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP) [online]","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2026.107024_bib0012","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1468-1331.2003.00669.x","article-title":"A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis [online]","volume":"10","author":"Carr\u00e1","year":"2003","journal-title":"Eur. j. neurol."},{"key":"10.1016\/j.msard.2026.107024_bib0013","unstructured":"Celius, E.G. et al., 2023. Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience. 10.3389\/fneur.2023.1060696."},{"issue":"16_supplement","key":"10.1016\/j.msard.2026.107024_bib0014","first-page":"88","article-title":"Early switch to fingolimod for achieving no evidence of multiple sclerosis disease activity: 7-year analysis of data from the TRANSFORMS study (P4.390)","author":"Cohen","year":"2017","journal-title":"Neurology."},{"issue":"9856","key":"10.1016\/j.msard.2026.107024_bib0015","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial [online]","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.msard.2026.107024_bib0016","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s10072-020-04380-y","article-title":"Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study [online]","volume":"41","author":"Comi","year":"2020","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2026.107024_bib0017","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40263-024-01066-3","article-title":"Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study [online]","volume":"38","author":"Costa-Frossard Fran\u00e7a","year":"2024","journal-title":"CNS. Drugs"},{"issue":"8","key":"10.1016\/j.msard.2026.107024_bib0018","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1212\/WNL.0000000000012323","article-title":"Secondary Progressive Multiple Sclerosis: New Insights [online]","volume":"97","author":"Cree","year":"2021","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.msard.2026.107024_bib0019","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/13524585231151951","article-title":"Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis [online]","volume":"29","author":"Daruwalla","year":"2023","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.msard.2026.107024_bib0020","article-title":"The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing\u2013remitting multiple sclerosis [online]","volume":"6","author":"Derfuss","year":"2020","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107024_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105570","article-title":"Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers [online]","volume":"86","author":"Diem","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107024_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1112193","article-title":"Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study","volume":"14","author":"Eichau","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107024_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104231","article-title":"Epidemiology of familial multiple sclerosis and its comparison to sporadic form in Markazi Province, Iran [online]","volume":"68","author":"Faraji","year":"2022","journal-title":"Mult. scler. relat. disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107024_bib0024","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/acn3.51282","article-title":"Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population [online]","volume":"8","author":"Fernandez-Diaz","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2026.107024_bib0025","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","article-title":"Early use of high-efficacy diseasemodifying therapies makes the difference in people with multiple sclerosis: an expert opinion [online]","volume":"269","author":"Filippi","year":"2022","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107024_bib0026","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.neurol.2022.11.012","article-title":"A decade of fingolimod in multiple sclerosis: Insights from a large real-world cohort study","volume":"179","author":"Gauer","year":"2023","journal-title":"Rev. Neurol."},{"issue":"19","key":"10.1016\/j.msard.2026.107024_bib0027","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1212\/WNL.0000000000003319","article-title":"Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients [online]","volume":"87","author":"Giovannoni","year":"2016","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.msard.2026.107024_bib0028","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis [online]","volume":"2024","author":"Gonzalez-Lorenzo","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2026.107024_bib0029","article-title":"Effectiveness of Natalizumab in Achieving No Evidence of Disease Activity (NEDA-3)\u2014Data From a Local Norwegian Cohort [online]","volume":"12","author":"Gulowsen Celius","year":"2021","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107024_bib0030","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/brain\/awab033","article-title":"Cortical involvement determines impairment 30 years after a clinically isolated syndrome [online]","volume":"144","author":"Haider","year":"2021","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2026.107024_bib0031","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-021-10673-9","article-title":"Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study [online]","volume":"269","author":"H\u00e4nninen","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107024_bib0032","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.msard.2017.12.015","article-title":"Worldwide prevalence of familial multiple sclerosis: A systematic review and meta-analysis [online]","volume":"20","author":"Harirchian","year":"2018","journal-title":"Mult. scler. relat. disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107024_bib0033","article-title":"Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis [online]","volume":"10","author":"Hauser","year":"2023","journal-title":"Neurol.(R) neuroimmunol. neuroinflammation"},{"issue":"3","key":"10.1016\/j.msard.2026.107024_bib0034","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis [online]","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2026.107024_bib0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study [online]","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107024_bib0036","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107024_bib0037","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241229325","article-title":"Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making? [online]","volume":"17","author":"Hoffmann","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.107024_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-40940-w","article-title":"Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials [online]","volume":"13","author":"Ingwersen","year":"2023","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.msard.2026.107024_bib0039","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis [online]","volume":"359","author":"Investigators","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107024_bib0040","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241285556","article-title":"Identification of alemtuzumab-suitable multiple sclerosis patients in Slovakia and sequencing of post-alemtuzumab immunomodulatory treatment [online]","volume":"17","author":"Kantorov\u00e1","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.msard.2026.107024_bib0041","article-title":"Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland [online]","volume":"4","author":"Kaufmann","year":"2018","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"issue":"16","key":"10.1016\/j.msard.2026.107024_bib0042","doi-asserted-by":"crossref","first-page":"e1560","DOI":"10.1212\/WNL.0000000000012690","article-title":"Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis [online]","volume":"97","author":"Koch","year":"2021","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.msard.2026.107024_bib0043","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41582-021-00556-y","article-title":"Apparent changes in the epidemiology and severity of multiple sclerosis [online]","volume":"17","author":"Koch-Henriksen","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107024_bib0044","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis pathology [online]","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"2","key":"10.1016\/j.msard.2026.107024_bib0045","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/ene.14589","article-title":"Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register [online]","volume":"28","author":"Lepore","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107024_bib0046","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00401-018-1818-y","article-title":"Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis [online]","volume":"135","author":"Luchetti","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.msard.2026.107024_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104059","article-title":"A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis","volume":"66","author":"Mathew","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2026.107024_bib0048","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s12031-020-01523-w","article-title":"Effect of rituximab on expanded disability status scale and relapse rate in multiple sclerosis patients [online]","volume":"70","author":"Mazdeh","year":"2020","journal-title":"J. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.msard.2026.107024_bib0049","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s41687-024-00822-9","article-title":"Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study [online]","volume":"8","author":"Meca-Lallana","year":"2024","journal-title":"J. Patient-Rep. Outcomes"},{"issue":"2","key":"10.1016\/j.msard.2026.107024_bib0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ene.13536","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis [online]","volume":"25","author":"Montalban","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107024_bib0051","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107024_bib0052","first-page":"47","article-title":"Natalizumab in multiple sclerosis: a single centre real-world study [online]","author":"Onder","year":"2024","journal-title":"J. Mult. Scler. Res."},{"issue":"5","key":"10.1016\/j.msard.2026.107024_bib0053","first-page":"346","article-title":"Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the \u201cno evidence of disease activity\u201d parameter [online]","volume":"36","author":"Pato Pato","year":"2021","journal-title":"Neurol. (Engl. Ed.)"},{"issue":"3","key":"10.1016\/j.msard.2026.107024_bib0054","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s13311-020-00847-0","article-title":"Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study [online]","volume":"17","author":"Prosperini","year":"2020","journal-title":"Neurotherapeutics."},{"issue":"17","key":"10.1016\/j.msard.2026.107024_bib0055","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology [online]","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.msard.2026.107024_bib0056","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/WNF.0000000000000503","article-title":"Effectiveness and Safety of Early High-Efficacy Versus Escalation Therapy in Relapsing-Remitting Multiple Sclerosis in Argentina [online]","volume":"45","author":"Rojas","year":"2022","journal-title":"Clin. neuropharmacol."},{"key":"10.1016\/j.msard.2026.107024_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102672","article-title":"Time interval between disease onset and MS diagnosis during the last decades in Latin America [online]","volume":"48","author":"Rojas","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107024_bib0058","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort [online]","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107024_bib0059","article-title":"Early clinical effect of cladribine in patients with highly active multiple sclerosis in Mexico [online]","volume":"10","author":"Sauri-Suarez","year":"2024","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"issue":"8","key":"10.1016\/j.msard.2026.107024_bib0060","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/1352458517713668","article-title":"Comparative effectiveness of rituximab relative to IFN-\u03b2 or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry [online]","volume":"24","author":"Spelman","year":"2018","journal-title":"Mult. scler. (Houndmills Basingstoke Engl.)"},{"issue":"6","key":"10.1016\/j.msard.2026.107024_bib0061","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/1352458509103610","article-title":"Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: Results of a 2-year, double-blind, placebo-controlled, crossover study [online]","volume":"15","author":"Stelmasiak","year":"2009","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2026.107024_bib0062","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria [online]","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet, Neurol."},{"key":"10.1016\/j.msard.2026.107024_bib0063","article-title":"Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study [online]","volume":"763418","author":"Totaro","year":"2015","journal-title":"Mult. Scler. Int."},{"issue":"11\u201312","key":"10.1016\/j.msard.2026.107024_bib0064","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1177\/13524585231197076","article-title":"Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences [online]","volume":"29","author":"Uher","year":"2023","journal-title":"Mult. Scler. (Houndmills Basingstoke Engl.)"},{"issue":"5","key":"10.1016\/j.msard.2026.107024_bib0065","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/1352458520926869","article-title":"Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program [online]","volume":"27","author":"Wiendl","year":"2021","journal-title":"Mult. scler. (Houndmills Basingstoke Engl.)"},{"key":"10.1016\/j.msard.2026.107024_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105435","article-title":"Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines [online]","volume":"83","author":"Yamout","year":"2024","journal-title":"Mult. scler. relat. disord."},{"key":"10.1016\/j.msard.2026.107024_bib0067","article-title":"Cerebellar and\/or Brainstem Lesions Indicate Poor Prognosis in Multiple Sclerosis: A Systematic Review [online]","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107024_bib0068","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1590\/0004-282x-anp-2020-0303","article-title":"Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile [online]","volume":"79","author":"Ysrraelit","year":"2021","journal-title":"Arq. Neuro-Psiquiatr."},{"issue":"7","key":"10.1016\/j.msard.2026.107024_bib0069","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00415-024-12360-x","article-title":"Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study [online]","volume":"271","author":"Zangh\u00ec","year":"2024","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.107024_bib0070","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1007\/s00415-014-7446-0","article-title":"A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial [online]","volume":"261","author":"Ziemssen","year":"2014","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107024_bib0071","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1007\/s00415-021-10931-w","article-title":"Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany [online]","volume":"269","author":"Ziemssen","year":"2022","journal-title":"J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600060X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600060X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:04:42Z","timestamp":1785755082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482600060X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":71,"alternative-id":["S221103482600060X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107024","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment outcomes of high-efficacy disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: A longitudinal observational study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107024"}}